Liposome structures and methods of use thereof
The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.
1. A liposome comprising non-pore forming pHLIP polypeptide monomers covalently attached to polar headgroups of phospholipids in the lipid bilayer of said liposome, wherein the hydrophobic phospholipid tail region of the lipid bilayer of said liposome is substantially free of said pHLIP polypeptides.
2. The liposome of claim 1 , wherein said liposome further comprises a cargo inside of said liposome or inside of said lipid bilayer.
3. The liposome of claim 1 , wherein said cargo comprises a therapeutic compound.
4. The liposome of claim 1 , wherein said cargo comprises a polar composition.
5. The liposome of claim 1 , wherein said liposome further comprises a hydrophobic cargo incorporated into said lipid bilayer.
6. The liposome of claim 1 , wherein said liposome further comprises a lipid bilayer-tethered cargo.
7. The liposome of claim 6 , wherein said tethered cargo is attached to a lipid by a cleavable or non-cleavable bond.
8. The liposome of claim 6 , wherein said tethered cargo is attached to a lipid by a S-S bond.
9. A method of delivering a cargo into a target cell comprising contacting said target cell with cargo-loaded pHLIP + liposomes according to claim 1 , wherein at least 10% more of said cargo is delivered to the cytoplasm of said target cell compared to the amount delivered using pHLIP − liposomes.
10. The method of claim 9 , wherein said target cell is characterized by a microenvironment comprising a low pH.
11. The method of claim 9 , wherein said pHLIP+liposomes fuse with a cell membrane of said target cell.
12. The method of claim 9 , wherein said pHLIP+liposomes both fuse with a cell membrane of said target cell and are taken up by said cell by endocytosis.
13. The method of claim 9 , wherein said pHLIP+liposomes preferentially fuse with a membrane of an endosomal compartment and a lysosomal compartment of said target cell after uptake by endocytosis.
14. The method of claim 9 , wherein said target cell is a tumor cell, ischemic cell, inflamed cell, bacterially-infected cell, fungus-infected cells, or virally-infected cell.
15. The method of claim 9 , wherein said cargo comprises ceramide, a deoxyribonucleotide (DNA) binding agent, a small interfering ribonucleic acid (RNA), a DNA, a polar toxin, an inhibitor, paclitaxel, or doxorubicin.
16. A pharmaceutical composition comprising the liposome of claim 1 .
17. The liposome of claim 1 , wherein said pHLIP polypeptides are located outside of the lipid bilayer of said liposome.
18. The liposome of claim 1 , wherein the amino-terminal end of said pHLIP polypeptide is covalently attached to said phospholipid.
19. The liposome of claim 1 , wherein the carboxy-terminal end of said pHLIP polypeptide is covalently attached to said phospholipid.